Oropharyngeal & hypopharyngeal cancer

The oropharynx includes the tonsils, tongue base, soft palate and back of the middle throat. The hypopharynx lies lower, around and behind the voice box, and includes the piriform sinuses. Most cancers at these sites are squamous cell carcinomas, but pathology must confirm the type.

A neck lump, persistent sore throat, painful or difficult swallowing, referred ear pain or voice change can prompt investigation. A small tonsil or tongue-base primary may first be noticed through a neck node. Endoscopy and biopsy establish the diagnosis; CT or MRI maps local and nodal disease, with PET/CT or other imaging when indicated.

Newly diagnosed oropharyngeal squamous cancer should be assessed for high-risk HPV association. Tissue p16 staining is a commonly used surrogate; HPV-specific testing is needed in selected situations, including discordant morphology and p16 findings. The report should identify the test and conclusion rather than simply saying ‘HPV positive’.

AJCC Version 9 for HPV-associated oropharyngeal cancer took effect in 2026. HPV-independent oropharyngeal and hypopharyngeal cancers continue under the relevant 8th-edition system. Compare T, N, M, HPV classification and the staging edition together. A lower stage number in HPV-associated disease does not necessarily mean that less treatment is appropriate.

HPV testing is not routinely used to assign a favorable prognosis to primary hypopharyngeal squamous cancer. For HPV-associated oropharyngeal cancer, the infection may have occurred many years earlier; the diagnosis cannot identify when it was acquired.

Selected localized tumors may be treated by transoral surgery with appropriate neck management or by definitive radiation. A robotic or laser approach is a surgical technique, not a guarantee that radiation can be avoided. The likelihood of clear margins, nodal disease and postoperative treatment should be considered before choosing surgery.

For disease requiring definitive chemoradiation, cisplatin is commonly used when the patient can tolerate it. In HPV-positive disease, tumor extent and nodal burden guide whether concurrent systemic treatment is needed. After surgery, positive margins or extranodal extension can support chemoradiation; other risk factors may support radiation alone. Ask about the total burden of all likely treatments, not only the first procedure.

For selected patients, chemoradiation offers a larynx-preserving approach. Others need surgery, potentially removing part or all of the larynx and pharynx, followed by reconstruction and postoperative therapy. Tumor extent, cartilage invasion, airway obstruction, aspiration and baseline swallowing are central to choosing a path.

Keeping a severely damaged larynx in place can leave poor swallowing or an unsafe airway. Compare the chance of useful function after organ preservation with the expected rehabilitation after surgery. Feeding and airway support, including whether a permanent neck breathing opening would be needed, should be explained before treatment.

HPV-associated oropharyngeal cancer often responds well, but reducing treatment must be supported by the exact risk group and evidence. Trials replacing cisplatin with cetuximab in suitable HPV-positive patients did not preserve the same cancer outcomes. A targeted drug is not automatically an equally effective, gentler substitute.

Radiation-dose reduction and treatment omission continue to be studied. Do not lower or stop a prescribed course simply because p16 is positive or an early scan looks clear. A de-intensification proposal should specify the protocol, eligibility, expected benefit and how recurrence would be monitored.

For eligible adults with resectable locally advanced head-and-neck squamous cancer and PD-L1 CPS at least 1, the US pembrolizumab label includes treatment before surgery, then with postoperative radiation with or without cisplatin, and subsequently alone. This surgical pathway does not authorize routinely adding pembrolizumab to every definitive chemoradiation plan.

The evidence also deserves site-specific interpretation. HPV-positive tumors were a small minority in KEYNOTE-689. Its small exploratory hypopharyngeal subgroup did not show the overall trial’s favorable event-free-survival pattern, with substantial uncertainty. This does not establish harm for every patient, but it is a reason for an individualized discussion rather than a blanket promise of benefit.

For metastatic or unresectable recurrent disease, US first-line pembrolizumab alone requires CPS at least 1; its combination with platinum and fluorouracil does not have that threshold. Nivolumab is another labeled option after platinum progression. Prior immune treatment and the need for rapid symptom relief affect selection; switching PD-1 drugs after resistance is not automatically beneficial.

After definitive radiation or chemoradiation, response imaging is commonly planned around three months, allowing early inflammation to settle. Equivocal uptake or residual node enlargement may need repeat imaging or tissue assessment; convincing residual disease can require neck dissection. A scan performed too early can be misleading.

If recurrence is suspected, establish whether it is confined to the treated region, a new primary or distant spread. Salvage surgery or reirradiation may be possible in selected cases, but previous doses and tissue injury matter. HPV-related blood DNA tests are evolving and should not replace examination, imaging or confirmation of a suspicious finding.

Arrange dental review, nutrition assessment and speech/swallowing therapy before treatment when possible. Mouth soreness, dry mouth, altered taste, reduced jaw opening and neck stiffness can persist after tumor treatment. Swallowing exercises and diet changes should follow the rehabilitation team’s advice, particularly if aspiration is a concern.

Coughing during meals, repeated chest infections or weight loss can signal swallowing problems even when the throat looks healed. A feeding tube can support nutrition but does not replace swallowing assessment. New breathing difficulty, inability to manage saliva or substantial bleeding needs urgent medical attention.

• Record the precise site, histology, p16/HPV method and results, TNM findings and staging edition.
• Bring original scans, operative pathology, prior radiation plans and dates of platinum or immunotherapy.
• Include weight trend, feeding support, airway history and speech/swallowing assessments.